Axon reports Q4 2025 revenue of $797 million, up 39% year over year

Axon reported 2025 revenue of $2.8 billion, up 33% year-over-year, with Q4 revenue of $797 million (+39% YoY) and Software & Services revenue of $343 million (+40% YoY). Q4 GAAP net income was $3 million (non‑GAAP net income $178 million) and Adjusted EBITDA was $206 million (25.9% margin); full‑year Adjusted EBITDA margin was 25.5%. The company exited 2025 with $1.347 billion ARR (+35%), $7.4 billion of annual bookings and $14.4 billion of future contracted bookings, and provided 2026 guidance of 27–30% revenue growth and a 25.5% Adjusted EBITDA margin while setting 2028 targets of ~$6 billion revenue and ~28% Adjusted EBITDA; headwinds include margin pressure from global tariffs and elevated stock‑based compensation guidance ($590–$620M) and planned capex of $185–$215M. Net leverage is modest (net debt ~ $112M after financing), and management emphasizes AI product launches and recent acquisitions as growth drivers.

Analysis

Market structure: Axon (AXON) is the clear near-term winner — accelerating SaaS (ARR +35% YoY to $1.347B), record bookings ($7.4B annual, $14.4B future contracted) and AI-led product expansion (Axon Assistant, Vehicle Intelligence, Axon 911) give it stronger pricing power on recurring software versus legacy hardware vendors. Incumbent hardware-only vendors (e.g., legacy ALPR/fixed-camera players and some public-safety integrators) face share loss and margin pressure as customers shift to integrated AI workflows; tariffs and semiconductor supply tighten gross margins in Connected Devices (~47% GM). Cross-assets: AXON equity should exhibit elevated event-driven vols into Axon Week (April) and Q1 prints; corporate credit could tighten if execution sustains given $1.8B notes and small net debt (~$112M net), while USD/FX impact is minimal (17% international revenue).

Risk assessment: Key tail risks are regulatory restrictions on ALPR/real‑time surveillance (municipal bans or federal limits), AI liability/litigation, and integration failure of Carbyne/Prepared — any could cut Vehicle/911 TAM by 15–30% over 12–24 months. Time horizons: immediate (days–weeks) centered on guidance cadence and Axon Week; short-term (Q2–H1 2026) execution on ALPR deployments and Axon 911 integrations; long-term (to 2028) depends on scaling enterprise Body Mini and controlling stock‑based comp (guidance $590–620M SBC in 2026). Hidden dependency: government budget cycles and non‑appropriation clauses could convert large booked ARR into churn if funding gaps appear.

Key Decisions for Investors

• Establish a 2–3% long position in AXON ahead of Axon Week (April 2026) to capture product/catalyst optionality; add to 4–6% total on a confirmed guidance beat or ARR growth >30% YoY in Q1; trim to 50% exposure if ARR growth drops below 25% YoY or net revenue retention <120% for two consecutive quarters.
• Buy Jan‑2027 LEAP calls sized at 1–2% of portfolio (25–35% OTM) or construct a 9–12 month call spread to capture 2026–2028 AI/911 rollout upside while capping premium; close or roll if AXON fails to secure early 2026 ALPR deployments or Carbyne integration milestones within 6 months.
• Implement a pair trade: Long AXON (60% notional) / Short Motorola Solutions (MSI) (40% notional) for a 12‑month horizon to express SaaS/AI share gains; unwind if MSI outperforms AXON by >15% absolute or if AXON software gross margin <70%.
• If unwilling to buy outright, sell 3‑month 7–10% OTM puts on AXON (limit 1% portfolio notional) to collect premium and potentially acquire shares on pullback; use a stop-loss to exit if AXON gaps down >18% on regulatory action (e.g., municipal ALPR ban) or SBC guidance rises above $620M.